Sean Chappin, MD
Addiction Medicine · Albany, NYNPI 1679740427
Payments from drug & device makers
Across 1,051 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$2K
- Vanda Pharmaceuticals Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- plus $7K from 22 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 222 | $4,212 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 130 | $2,360 |
| Johnson & Johnson(2 entities) | 73 | $2,002 |
| Vanda Pharmaceuticals Inc. | 89 | $1,893 |
| Otsuka America Pharmaceutical, Inc. | 73 | $1,369 |
| Alkermes, Inc. | 53 | $1,253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 80 | $1,202 |
| Lundbeck LLC | 60 | $1,063 |
| Neurocrine Biosciences, Inc. | 45 | $840 |
| Axsome Therapeutics, Inc. | 49 | $835 |
| Teva Pharmaceuticals USA, Inc. | 40 | $785 |
| Corium, LLC | 37 | $746 |
| Sunovion Pharmaceuticals Inc. | 38 | $606 |
| E.r. Squibb & Sons, L.L.C. | 13 | $237 |
| Supernus Pharmaceuticals, Inc. | 12 | $219 |
| Orexo US, Inc. | 6 | $116 |
| Avanir Pharmaceuticals, Inc. | 7 | $99 |
| Shire North American Group Inc | 4 | $74 |
| Eisai Inc. | 3 | $69 |
| Collegium Pharmaceutical, Inc. | 3 | $68 |
| Almatica Pharma LLC | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| Ironshore Pharmaceuticals Inc. | 2 | $45 |
| Merck | 3 | $44 |
| Biogen | 1 | $27 |
| Indivior Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $17 |
How this compares
$20,324 in reported general payments places this provider in the 90th percentile of 125 addiction medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other addiction medicine in Albany
- Muhammed SaifAlbany$3K
- Angad MadanAlbany$450
- Alain LitwinBronx$1.8M
- Joshua LeeNew York$1.1M
- Julia ArnstenBronx$292K
- Edmond HakimiCalverton$125K
- Dawn HarbatkinAmherst$111K
- James WolbergNew York$45K
- Mohammed IsmailTroy$43K
- John MarianiNew York$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.